Phase III Program for AVE0010/ZP10 Licensed From Sanofi-Aventis (France) will Begin in the First Quarter of 2008
COPENHAGEN, DENMARK--(Marketwire - February 12, 2008) - Today Sanofi-Aventis announced that after consultation with the healthcare authorities, the Phase III program for the GLP-1 agonist AVE0010/ZP10 licensed from Zealand Pharma A/S will begin in the first quarter of 2008.